Buchanan Ingersoll & Rooney was noted in a May 27, 2010, article published in Law360. The article, titled "USPTO Affirms Abbott Protein Patent In War With Yeda," reported on the firm's representation of Abbott GmbH & Co. KG in its 14-year dispute with Yeda Research and Development Co. Ltd. involving Tumor Necrosis Factor α binding proteins.

As explained in the article, "The U.S. Patent and Trademark Office's Board of Patent Appeals and Interferences on Wednesday (May 26, 2010) awarded Abbott the benefit of its earliest-filed application and entered judgment against Yeda, which had long contended that it made reference to the binding protein prior to Abbott's patent application, rendering Abbott’s patent claims invalid. … The board declared that Abbott's May 9, 1989, filing of an application for a German patent covering the protein, which is protected by U.S. Patent Number 5,344,915, beat out Yeda's May 18, 1989, filing date, which had initially been granted priority."